Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma
NCT01005472
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
Adult Trials: 18+ Years
- Histologically confirmed Stage IIIC unresectable cutaneous or mucosal melanoma with measureable disease or stage IV cutaneous, mucosal or ocular melanoma with measureable disease.
- ECOG performance status of 0-2
- age greater than or equal to 18 years
- ANC ≥ 1,500/µL
- Platelet count ≥ 100,000/µL
- Hemoglobin ≥ 10.0 g/dL
- Creatinine ≤ 2 times upper limit of normal (ULN)
- Total bilirubin ≤ 2 times ULN
- LDH ≤ 5 times ULN
- AST or ALT ≤ 2.5 times ULN (≤ 5 times ULN if liver metastasis is present)
- LVEF ≥ 50% on screening ECHO
- women of childbearing potential must have a negative urine or serum pregnancy test upto 28 days prior to commencement of dosing.
- Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment
- Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study procedures
- before study entry , written informed consent must be obtained. Written informed consent must be obtained from patient prior to performing any study related procedures.
- pregnant or nursing
- any following within the past 12 months:
- Myocardial infarction
- Severe and/or unstable angina
- Coronary and/or peripheral artery bypass graft
- Symptomatic congestive heart failure
- Cerebrovascular accident or transient ischemic attack
- Pulmonary embolism
- ongoing cardiac dysrhythmias ≥ grade 2, according to NCI CTCAE v3.0
- prolonged QTc interval on baseline EKG
- uncontrolled hypertension (i.e., blood pressure > 150/100 mm Hg despite optimal
medical therapy)
- pre-existing thyroid abnormality with thyroid function that cannot be maintained in
the normal range with medication
- any known clinically uncontrolled infectious disease, including HIV positivity or
AIDS-related illness
- severe acute or chronic medical or psychiatric condition or laboratory abnormality
that may increase the risk associated with study participation or study drug
administration or may interfere with the interpretation of study results, and, in the
judgment of the investigator, would make the patient inappropriate for study entry
- prior chemotherapy for melanoma, except for chemotherapy given during isolated limb
perfusion for stage IIIC disease
- Prior adjuvant immunotherapy and/or immunotherapy for metastatic disease allowed
- prior major surgery, radiotherapy, or immunotherapy within 4 weeks of starting therapy
- treatment with potent CYP3A4 inhibitors 7 days before study dosing
- treatment with potent CYP3A4 inducers 12 days before study dosing
- concurrent treatment on another clinical trial (Concurrent participation on supportive
care trials or non-treatment trials (e.g., quality-of-life trials) allowed).
- concurrent chemotherapy, immunotherapy, biological therapy, or investigational drugs
- concurrent drugs with dysrhythmic potential, including any of the following:
- Terfenadine
- Quinidine
- Procainamide
- Disopyramide
- Sotalol
- Probucol
- Bepridil
- Haloperidol
- Risperidone
- Indapamide
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- San Francisco, California
- Los Angeles, California
| Descriptive Information | ||||
|---|---|---|---|---|
| Brief Title ICMJE | Temozolomide and Sunitinib Malate in Treating Patients With Stage III or Stage IV Malignant Melanoma | |||
| Official Title ICMJE | A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma | |||
| Brief Summary | RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Sunitinib malate may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor. Giving temozolomide together with sunitinib malate may kill more tumor cells. Phase II was never conducted due to toxicity in phase I. PURPOSE: This phase I/II trial is studying the side effects and best dose of sunitinib malate when given together with temozolomide and to see how well they work in treating patients with stage III or stage IV malignant melanoma. | |||
| Detailed Description | OBJECTIVES: Primary
Secondary
OUTLINE: This is a phase I, dose-escalation study of sunitinib malate followed by a phase II study. Patients receive oral sunitinib malate once daily and oral temozolomide once daily on days 1-42. Treatment repeats every 56 days for up to 1 year in the absence of disease progression or unacceptable toxicity. After completion of study therapy, patients are followed up very 6 months for up to 5 years. Phase II was never conducted due to toxicity in phase I. | |||
| Study Type ICMJE | Interventional | |||
| Study Phase ICMJE | Phase 1 | |||
| Study Design ICMJE | Allocation: N/A Intervention Model: Single Group Assignment Masking: None (Open Label) Primary Purpose: Treatment | |||
| Condition ICMJE | Metastatic Melanoma | |||
| Intervention ICMJE |
| |||
| Study Arms ICMJE | Experimental: sunitinib malate, temozolomide
Interventions:
| |||
| Publications * | Not Provided | |||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | ||||
| Recruitment Information | ||||
| Recruitment Status ICMJE | Completed | |||
| Actual Enrollment ICMJE | 16 | |||
| Original Estimated Enrollment ICMJE | 48 | |||
| Actual Study Completion Date ICMJE | January 17, 2018 | |||
| Actual Primary Completion Date | January 17, 2018 (Final data collection date for primary outcome measure) | |||
| Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria
| |||
| Sex/Gender ICMJE |
| |||
| Ages ICMJE | 18 Years and older (Adult, Older Adult) | |||
| Accepts Healthy Volunteers ICMJE | No | |||
| Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | |||
| Listed Location Countries ICMJE | United States | |||
| Removed Location Countries | ||||
| Administrative Information | ||||
| NCT Number ICMJE | NCT01005472 | |||
| Other Study ID Numbers ICMJE | CDR0000634373 UCLA-0711052 SPRI-P05513 PFIZER-GA6181FZ 10-001406 ( Other Identifier: UCLA IRB ) | |||
| Has Data Monitoring Committee | Yes | |||
| U.S. FDA-regulated Product | Not Provided | |||
| IPD Sharing Statement ICMJE | Not Provided | |||
| Responsible Party | Jonsson Comprehensive Cancer Center | |||
| Study Sponsor ICMJE | Jonsson Comprehensive Cancer Center | |||
| Collaborators ICMJE |
| |||
| Investigators ICMJE |
| |||
| PRS Account | Jonsson Comprehensive Cancer Center | |||
| Verification Date | April 2018 | |||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP | ||||